Drugs that contain Trametinib Dimethyl Sulfoxide

1. Drug name - MEKINIST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7378423 NOVARTIS Pyrimidine compound and medical use thereof
May, 2027

(4 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(8 years from now)

CN101912400A NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D] Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

CN101006086A NOVARTIS 5-Amido-2, 4, 7-Trioxy-3, 4, 7, 8-Tetrahydropyranyl Ether-2H-Naphthyridine [2,3-D] Pyrimidine Derivatives And Correlative Compound Used For Curing Cancer
Jun, 2025

(2 years from now)

CN101912400B NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D] Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

CN101006086B NOVARTIS For The 5 - -2, 4, 7 - -3, 4, 7, 8-Tetrahydro - -2H - Pyrido [2, 3-D] Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

CN102655753A NOVARTIS Combination
Oct, 2030

(8 years from now)

CN102655753B NOVARTIS Combined Medicine
Oct, 2030

(8 years from now)

IN200700102P4 NOVARTIS Pyrimidine Compound And Medical Use Thereof
Jun, 2025

(2 years from now)

IN237689B NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyridio[2,3-D]Pyrimidine Derivatives And A Pharmaceutical Composition Comprising The Same
Jun, 2025

(2 years from now)

EP2298768B9 NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

EP2298768B1 NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

EP2298768A1 NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

EP1761528A1 NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

EP1761528B1 NOVARTIS 5-Amino-2,4,7-Trioxo-3,4,7,8-Tetrahydro-2H-Pyrido[2,3-D]Pyrimidine Derivatives And Related Compounds For The Treatment Of Cancer
Jun, 2025

(2 years from now)

EP2488033A1 NOVARTIS Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor
Oct, 2030

(8 years from now)

EP2488033B1 NOVARTIS Combination Comprising An Mek Inhibitor And A B-Raf Inhibitor
Oct, 2030

(8 years from now)

EP2488033A4 NOVARTIS Combination
Oct, 2030

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof Jun, 2025

(2 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors Oct, 2030

(8 years from now)

US9271941 NOVARTIS Pharmaceutical composition Jan, 2032

(9 years from now)

US9155706 NOVARTIS Pharmaceutical composition Jan, 2032

(9 years from now)

US8580304 NOVARTIS Pharmaceutical composition Jan, 2032

(9 years from now)

US9399021 NOVARTIS Pharmaceutical composition Jan, 2032

(9 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment Aug, 2033

(10 years from now)

Treatment: Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; treatment of unresectable or metastatic melanoma; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; in combination with dabrafenib for the treatment of unresectable or metastatic melanoma.; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG TABLET;ORAL Prescription
EQ 1MG TABLET;ORAL Discontinued
EQ 2MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.